Erratum to: ‘Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial

Benzer Materyaller

• Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial
  Yazar:: Yardley, Denise A., ve diğerleri
  Baskı/Yayın Bilgisi: (2015)
• nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial
  Yazar:: Yardley, D A, ve diğerleri
  Baskı/Yayın Bilgisi: (2018)
• First-Line Doublet Chemotherapy for Metastatic Triple-Negative Breast Cancer: Circulating Tumor Cell Analysis of the tnAcity Trial
  Yazar:: Liu, Minetta C, ve diğerleri
  Baskı/Yayın Bilgisi: (2019)
• Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
  Yazar:: Von Hoff, Daniel D., ve diğerleri
  Baskı/Yayın Bilgisi: (2013)
• Phase II trial of combination nab-paclitaxel, carboplatin and gemcitabine in first line therapy of advanced urothelial carcinoma
  Yazar:: Alva, Ajjai, ve diğerleri
  Baskı/Yayın Bilgisi: (2013)